Sanofi: 'chasing the miracles of science to improve people's lives'
Sanofi is a leading pharmaceutical company that places a strong emphasis on innovation. Through groundbreaking scientific research, Sanofi strives to prevent and combat diseases. This mission is aptly captured in Sanofi's motto: “Chasing the miracles of science to improve people’s lives.”
Sanofi ranks among the top 10 pharmaceutical companies in Belgium, employing approximately 1,600 people across four locations: Ghent, Geel, Diegem, and Brussels.
In Ghent, on the former Ablynx site, Sanofi hosts its NANOBODY® R&D center, focusing on the development of medicines using the unique NANOBODY® technology. NANOBODY® molecules are based on a special type of antibodies naturally found in llamas and other camelids. These innovative and versatile proteins are particularly well-suited for the rapid development of new biological therapies for severe and life-threatening diseases.
Currently, Sanofi’s primary focus is on developing new treatments for inflammatory diseases, (auto)immune disorders, neurological conditions, rare diseases, and oncology. Examples of such conditions include asthma, COPD, atopic dermatitis, multiple sclerosis, diabetes, ulcerative colitis, Crohn’s disease, Pompe disease, and multiple myeloma.
A recent example of a new therapeutic NANOBODY® molecule discovered and developed at Sanofi Ghent is lunsekimig. This bispecific NANOBODY® molecule is specifically designed for the treatment of immune-mediated respiratory diseases such as asthma. It is currently undergoing clinical trials to evaluate its efficacy, safety, and tolerability, with promising results so far.
For more information about the NANOBODY® technology and Sanofi’s activities in Ghent, visit our website: Sanofi Nanobody Technology Platform.